Numinus Wellness (TSX.V: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, recently announced that it has secured two new Canadian psychedelic clinics to host the Canadian sites of the MAPS Public Benefit Corporation (MAPS PBC) study “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX).” Per the release, the two new clinics are fully compliant with Health Canada regulations and ready to provide MDMA-assisted therapy as part of the trial. The Montreal and Vancouver sites, hosted by Numinus, will continue to advance the study of the safety and efficacy of MDMA in treating severe PTSD, under the direction of MAPS PBC as study organizer. Numinus will also assist financially for the costs of the therapists that deliver the therapeutic intervention in Numinus clinics during the trial. “We are thrilled that our two new locations, which are purpose-developed for psychedelic-assisted therapy, regulatorily compliant and leading in industry standards, can be used to help advance this crucial work on psychedelic medicine. We look forward to deepening our collaboration with MAPS while expanding the resources and solutions available to those suffering from PTSD,” Numinus CEO Payton Nyquvest stated in the news release.
To view the full press release, visit https://ibn.fm/rlpTG
About Numinus Wellness
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. The Numinus team is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. For more information, visit the company’s website at www.Numinus.ca.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.